GSA Capital Partners LLP Sells 27,220 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

GSA Capital Partners LLP lowered its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 42.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,662 shares of the company’s stock after selling 27,220 shares during the period. GSA Capital Partners LLP’s holdings in 4D Molecular Therapeutics were worth $407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the company. Redmile Group LLC purchased a new position in 4D Molecular Therapeutics during the first quarter valued at approximately $40,189,000. Assenagon Asset Management S.A. increased its holdings in 4D Molecular Therapeutics by 238.3% during the third quarter. Assenagon Asset Management S.A. now owns 1,543,414 shares of the company’s stock valued at $16,684,000 after buying an additional 1,087,147 shares during the period. RA Capital Management L.P. increased its holdings in 4D Molecular Therapeutics by 21.3% during the first quarter. RA Capital Management L.P. now owns 5,051,511 shares of the company’s stock valued at $160,941,000 after buying an additional 888,300 shares during the period. Vanguard Group Inc. increased its holdings in 4D Molecular Therapeutics by 25.3% during the first quarter. Vanguard Group Inc. now owns 2,339,943 shares of the company’s stock valued at $74,551,000 after buying an additional 473,094 shares during the period. Finally, Panagora Asset Management Inc. increased its holdings in 4D Molecular Therapeutics by 247.7% during the second quarter. Panagora Asset Management Inc. now owns 354,857 shares of the company’s stock valued at $7,448,000 after buying an additional 252,789 shares during the period. Institutional investors own 99.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on FDMT shares. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. Chardan Capital reaffirmed a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Royal Bank of Canada cut their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. Leerink Partners reaffirmed an “outperform” rating and issued a $36.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Finally, Morgan Stanley began coverage on shares of 4D Molecular Therapeutics in a report on Thursday. They issued an “underweight” rating and a $8.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $42.13.

4D Molecular Therapeutics Price Performance

NASDAQ FDMT opened at $7.99 on Friday. The company has a market capitalization of $369.38 million, a PE ratio of -2.80 and a beta of 2.82. The company has a fifty day moving average of $9.72 and a 200 day moving average of $16.66. 4D Molecular Therapeutics, Inc. has a 1 year low of $7.32 and a 1 year high of $36.25.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.